Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

 

Source:  Mangoceuticals, Inc. 2/6/2025

Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences (“Vipragen”), an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration with Intramont Technologies, Inc. (“Intramont”).

Building on strong preliminary results, the Company is advancing to the next stage of research while also engaging Vipragen to structure a cohort for evaluating its patented respiratory illness prevention technology against the H5N1 virus (Avian Influenza). The H5N1 cohort is intended to run concurrently with the ongoing H1N1 study.

This milestone follows promising results from the initial H1N1 animal trial, which demonstrated a significant reduction in viral load. These findings underscore the potential of the technology and provide a strong foundation for continued exploration and expanded applications. The H1N1 and forthcoming H5N1 studies utilize Mangoceuticals’ proprietary formulation of advanced polyphenol and zinc chemistry.

Jacob Cohen, Founder and CEO of Mangoceuticals, commented: “Our ability to progress with this study reflects the robust potential of our innovative platform. The inclusion of H5N1 as part of the next leg of our research allows us to address another pressing global health concern while demonstrating our commitment to groundbreaking solutions for respiratory illnesses.”

Dr. Douglas Christianson, the Company’s Director of Medical Research and Product Innovation, added: “This next phase of advancement for H1N1 and the development of an H5N1 cohort highlight the versatility of our platform technology. These initiatives reaffirm our dedication to addressing evolving viral threats through innovation and cutting-edge research.”

With respiratory infections posing a growing global health concern, Mangoceuticals remains committed to leveraging its patented technology to combat these threats effectively. The company anticipates disclosing the final results of its studies upon completion and after ensuring proper intellectual property protections through provisional filings.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.